A5053802334- Bladder and Urothelial Cancer Treatments
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Urinary and Genital Oncology Studies
- Renal cell carcinoma treatment
- Urological Disorders and Treatments
- Immunotherapy and Immune Responses
- Urinary Bladder and Prostate Research
- Virus-based gene therapy research
- Cancer Research and Treatments
- Multiple and Secondary Primary Cancers
- Pelvic floor disorders treatments
- Urologic and reproductive health conditions
- Hormonal and reproductive studies
- Renal and related cancers
- Cancer, Lipids, and Metabolism
- Radiopharmaceutical Chemistry and Applications
- Ureteral procedures and complications
- Organ Donation and Transplantation
- Pediatric Urology and Nephrology Studies
- Monoclonal and Polyclonal Antibodies Research
- Molecular Biology Techniques and Applications
- Esophageal Cancer Research and Treatment
- Renal and Vascular Pathologies
- Kidney Stones and Urolithiasis Treatments
Ehime University
2017-2025
Ehime University Hospital
2023-2024
Ebara (Japan)
2018
Obayashi (Japan)
2018
Okayama University
2004-2014
Citizens Specialty Hospitals
2014
Hiroshima City Asa Citizens Hospital
2014
Okayama University Hospital
2008-2012
City Hospital
2012
Okayama Medical Center
2012
Neuroendocrine prostate carcinoma (NEPC) accounts for less than 1% of neoplasms and has extremely poorer prognosis the typical androgen receptor pathway-positive adenocarcinoma (ARPC). However, very few cases in which de novo NEPC APRC are diagnosed simultaneously same tissue have been reported. We report herein a 78-year-old man metastatic coexisting with ARPC treated at Ehime University Hospital. Visium CytAssist Spatial Gene Expression analysis (10× genetics) was performed using...
We conducted a Phase I study of in situ herpes simplex virus thymidine kinase (HSV-tk) plus ganciclovir (GCV) gene therapy, which was approved by the Japanese government as first prostate cancer therapy trial. Major inclusion criteria were local recurrence after hormonal and no metastasis. Adv.HSV-tk injected directly into escalating doses from 109 to 1010 infection units, followed intravenous administration GCV for 14 days. Eight patients received nine courses this therapy. The detection...
Serological expression cloning of antigens eliciting a humoral immune response to syngeneic mouse sarcoma identified pem (mouse placenta and embryonic gene) as new member the cancer/testis family. To identify human homologue , sequences -related expressed sequence tags from testis were used PCR primers for amplification using cDNA. However, rather than another gene, designated OY-TES-1 was isolated found be proacrosin binding protein sp32 precursor originally in mouse, guinea pig, pig. maps...
Abstract Introduction In order to elucidate the influence of hormone‐releasing hormone (LH‐RH) agonist therapy cessation on pituitary/testicular function and its clinical implications, we investigated prospectively hormonal (luteinizing hormone: LH; testosterone: T) responses in patients with prostate cancer who received long‐term LH‐RH 10 therapy. Patients Methods A consecutive 32 had over 24 months were enrolled. As a baseline, T LH measured at time cessation, monthly for 3 months,...
NY-ESO-1 specific humoral responses are frequently observed in patients with various types of antigen expressing tumors. In a large proportion antibody-positive NY-ESO-1-specific CD8 T-cells can also be detected suggesting that monitoring the immune response may relevant and more practical surrogate for estimating overall against clinical vaccine studies. We have immunized 9 cancer full length protein formulated cholesterol-bearing hydrophobized pullulan (CHP-NY-ESO-1) investigated NY-ESO-1....
Study Type – Therapy (case series) Level of Evidence 4 OBJECTIVE To explore whether levels nerve growth factor (NGF) in expressed prostatic secretions (EPS) are correlated with symptom severity chronic prostatitis (CP) and pelvic pain syndrome (CPPS). PATIENTS AND METHODS All patients CP/CPPS underwent a complete history physical examination, were scored according to the National Institutes Health Chronic Prostatitis Symptom Index (NIH‐CPSI). Expressed secretion samples from 20 four...
The prognosis of patients with progressive prostate cancers that are hormone refractory and/or have bone metastasis is poor. Multiple therapeutic targets to improve cancer patient survival been investigated, including orphan GPCRs. In our study, we identified G Protein-Coupled Receptor Class C Group 5 Member A (GPRC5A) as a candidate molecule using integrative gene expression analyses registered data sets for cell lines. Kaplan-Meier analysis TCGA revealed who high GPRC5A had significantly...
It has been suggested that aging of the immune system (immunosenescence) results in a decline acquired response, which is associated with an increase age-related tumorigenesis. T-cell senescence plays critical role immunosenescence and involved function, increases susceptibility to certain cancers. However, it shown CD8+ T cells senescent phenotype acquire natural killer (NK) cell-like function are tumor elimination. Therefore, immunity remains be elucidated. In this study, we investigated...
Abstract Background Pelvic lymph node dissection is a procedure performed in gastroenterological surgery, urology, and gynecology. However, due to discrepancies the understanding of pelvic anatomy among these departments, cross‐disciplinary discussions have not been easy. Recently, with rapid spread robotic importance visual information has become even more significant. In this project, we attempted clarify shared through discussions. Method From May 2020 November 2021, total 11 were held...
Abstract NY‐ESO‐1 is a prototypic cancer/testis antigen. In recent phase I clinical trial, we vaccinated 13 patients bearing NY‐ESO‐1‐expressing tumors with complex of cholesterol‐bearing hydrophobized pullulan (CHP) and protein (CHP‐NY‐ESO‐1) showed efficient induction antibody, CD4 CD8 T cell responses using peripheral blood from the patients. our study, analyzed heteroclitic serological in those after vaccination. Serological response against 11 tumor antigens including MAGE‐A1, MAGE‐A3,...